Colchicine is a 500 microgram anti-inflammatory tablet for adults with acute gout and selected inflammatory conditions. It helps control inflammation triggered by urate crystals without lowering uric acid levels.
Colchicine is an anti-inflammatory medicine supplied as 500 microgram tablets. It is used for adults with acute gout and may be prescribed to prevent gout flares or manage familial Mediterranean fever.
Each tablet contains 500 micrograms of colchicine. Colchicine belongs to a group of anti-inflammatory medicines with a narrow therapeutic range, meaning that taking more than prescribed can cause serious toxicity. It is used for short-term gout flare treatment, flare prevention during urate-lowering therapy, and selected cases of familial Mediterranean fever.
Colchicine does not lower uric acid.
The FDA describes colchicine as a microtubule inhibitor. Microtubules are tiny structural fibres inside cells; colchicine disrupts their assembly, reducing the movement and activation of inflammatory cells at the affected joint [1].
Colchicine tablets are swallowed with water. The prescribed schedule depends on the reason for treatment, kidney function, liver function, age, and other medicines.
Common prescribing approaches include:
The margin for dosing errors is small.
NHS guidance explains that colchicine schedules differ according to the condition being treated and that prescribed limits must not be exceeded, since overdose can be life-threatening [3]. For patients in the UAE, the treatment plan should also account for medicines already prescribed through MOHAP-regulated clinical care.
During a gout flare, monosodium urate crystals activate the immune system inside a joint. Neutrophils, a type of white blood cell, enter the area and release inflammatory signals that cause swelling, heat, severe pain, and restricted movement.
Colchicine binds to tubulin, a protein needed to form microtubules. This slows neutrophil migration, reduces inflammatory signalling, and limits the inflammatory response around urate crystals. Relief is most useful when treatment begins early in a flare, before inflammation becomes fully established.
Unlike medicines that lower uric acid, colchicine does not dissolve crystals or correct long-term hyperuricaemia. Its role is to control inflammation. The European Alliance of Associations for Rheumatology includes low-dose colchicine among recommended options for managing acute gout flares, alongside anti-inflammatory alternatives selected according to individual risks [2].
It reduces inflammation triggered by urate crystals without lowering the body’s uric acid level.
Colchicine is often chosen when early treatment is possible and when an anti-inflammatory option is needed without using a non-steroidal anti-inflammatory drug. The best choice depends on kidney function, ulcer history, cardiovascular risk, diabetes, infection risk, and interacting medicines.
| Treatment approach | Main action | When it may be preferred |
|---|---|---|
| Colchicine | Limits neutrophil-driven inflammation | Early gout flare, flare prevention, familial Mediterranean fever |
| NSAID therapy | Reduces inflammatory prostaglandins | Suitable adults without significant renal, ulcer, bleeding, or cardiovascular restrictions |
| Oral corticosteroid therapy | Broadly suppresses inflammation | When colchicine or NSAIDs are unsuitable, with prescriber-directed dosing |
Colchicine can be useful for people who cannot take NSAIDs because of stomach-ulcer risk or anticoagulant treatment. Its limitation is the extensive interaction profile and the need for dose reduction or avoidance in renal and hepatic impairment. Corticosteroids may act quickly, though they can raise blood glucose and may be less suitable during uncontrolled infection.
Avoid colchicine or use it only under specialist-directed dosing if you have:
High-risk interactions include clarithromycin, erythromycin, ketoconazole, itraconazole, ciclosporin, verapamil, diltiazem, ritonavir-containing antiviral therapy, and some other strong CYP3A4 or P-glycoprotein inhibitors. Combining these medicines can raise colchicine concentrations to dangerous levels. Statins and fibrates may also increase the chance of muscle toxicity.
Grapefruit and grapefruit juice can increase colchicine exposure.
Pregnancy and breastfeeding require individual medical assessment. Colchicine may be used in selected people with familial Mediterranean fever, though the dose and monitoring plan should be determined by the treating clinician. The WHO Model List of Essential Medicines includes colchicine for familial Mediterranean fever, reflecting its established role in this specific inflammatory condition [5].
Colchicine is not for you if you have previously had a severe allergic reaction to colchicine or if a prescriber has told you that colchicine is unsuitable because of serious kidney or liver impairment.
Digestive effects are the most common limitation with colchicine. Diarrhoea, nausea, abdominal cramping, vomiting, and reduced appetite can occur, often when the dose is too high for the individual or when another medicine raises colchicine levels.
Diarrhoea is the usual limiting effect.
Less common but medically serious reactions need urgent assessment:
Colchicine toxicity can affect the gut, bone marrow, muscles, nerves, kidneys, and heart. Risk rises sharply when colchicine is combined with medicines that inhibit CYP3A4 or P-glycoprotein, two systems that normally help the body clear the medicine. The American College of Rheumatology advises choosing gout-flare therapy according to comorbidities and concurrent treatment, rather than treating every flare with the same regimen [4].
In clinical practice, doctors often separate two goals: controlling today’s flare and preventing the next one. Colchicine can help with the first goal, yet it does not replace long-term urate-lowering treatment when recurrent gout is driven by persistently raised uric acid. Early use tends to provide better flare control than waiting until swelling has peaked. Doctors also pay close attention to kidney function because the same tablet regimen may be excessive for someone with reduced clearance. A person taking several long-term medicines may need a different option even when colchicine worked well in the past. EMA pharmacovigilance principles also place interaction screening at the centre of medicines with a narrow therapeutic range.
Colchicine is most useful when started early, often within the first day of symptoms. Pain and swelling may begin easing within one to two days, while full resolution can take longer depending on flare severity. The NHS updated its colchicine patient guidance in 2024 and continues to describe it as a short-term treatment for gout symptoms. Lack of immediate relief is not a reason to exceed the prescribed dose.
Daily use may be prescribed for gout-flare prevention or familial Mediterranean fever. The dose, duration, and monitoring needs differ from a short acute gout course. The WHO’s 2023 Model List of Essential Medicines recognises colchicine for familial Mediterranean fever, where regular use may reduce inflammatory episodes. Daily treatment still requires interaction screening and consideration of kidney and liver function.
Alcohol does not create the same direct clearance interaction as clarithromycin or ciclosporin, yet it can trigger gout flares and worsen dehydration after vomiting or diarrhoea. Beer and spirits can raise uric acid in susceptible people, while any alcohol excess may make gout control harder. EULAR’s 2016 gout recommendations include lifestyle management alongside medicine-based flare control. Limiting alcohol during an active flare is a practical choice.
Strong CYP3A4 and P-glycoprotein inhibitors are the major concern because they can sharply increase colchicine exposure. Clarithromycin, certain antifungals, ciclosporin, verapamil, diltiazem, and ritonavir-containing treatments are examples. The FDA colchicine prescribing information, revised in 2023, lists serious and fatal toxicity reports with interacting medicines. Muscle symptoms also need attention when colchicine is used with statins or fibrates.
No. Colchicine targets inflammation caused by urate crystals; it does not lower serum urate or remove crystal deposits from joints. Long-term gout prevention may require a urate-lowering medicine when recurrent attacks, tophi, kidney stones, or persistently elevated uric acid are present. The American College of Rheumatology guideline published in 2020 separates anti-inflammatory flare treatment from long-term urate-lowering management. Both strategies can be used in the same care plan.
Treat a suspected overdose as urgent, even if symptoms are mild at first. Nausea, vomiting, abdominal pain, and diarrhoea may appear early, followed later by more serious complications involving blood cells, muscles, kidneys, or the heart. Contact emergency medical services or a poison centre immediately and provide the exact number of tablets and timing of doses. The FDA prescribing information from 2023 describes colchicine overdose as potentially fatal. MOHAP-aligned clinical care treats suspected colchicine overdose as an emergency because serious toxicity can be delayed.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (9.4x4.3x0.3 in. or 24x11x0.7 cm) and its contents cannot be seen.
I started the tablets on the first evening of a big-toe flare. The pain was still there the next morning, but I could put weight on the foot by the second day. I had mild loose stools, so my doctor kept me on the planned amount rather than increasing it.
I had used anti-inflammatory tablets before, but they irritated my stomach. Colchicine helped the swelling reduce over a few days. I made the mistake of taking a missed tablet too close to the next one and felt nauseated for most of the day.
I took it consistently for several months and had fewer attacks. The routine was easy once it became part of my morning medicines. My specialist adjusted the plan after reviewing my blood tests.
The joint pain improved, though diarrhoea started after the second day. I stopped taking extra doses for the pain and contacted my clinic. The flare settled, but I learned that more tablets were not the answer.
